|
Delayed
Börse Stuttgart
18:31:55 25/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.001000 EUR | -33.33% |
|
0.00% | -25.00% |
| 09-22 | WINNERS & LOSERS: Petro Matad sinks on PetroChina blow; Midwich up | AN |
| 09-14 | WINNERS & LOSERS: Tribal to sell assets; Brave Bison ups System1 tilt | AN |
| Market Cap | 3.37M 4.46M 3.91M 3.69M 6.3M 427M 6.35M 44.21M 17.12M 218M 16.74M 16.37M 701M | P/E 2024 |
-0.13x | P/E 2025 | -5.88x |
|---|---|---|---|---|---|
| Enterprise Value | 3.27M 4.33M 3.8M 3.59M 6.12M 415M 6.16M 42.93M 16.63M 212M 16.25M 15.9M 681M | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
94.63% | Yield 2024 * |
-
| Yield 2025 | - |
Börse StuttgartEUR
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| LVRT | Delayed | |
Deutsche Boerse AG
| 1RT | Delayed | |
|
Börse Stuttgart
| 1RT | Delayed |
| 23/05/25 | Nuformix : Prospectus | PU |
| 05/10/23 | Nuformix to fund its unlicensed programs with NXP001 windfall | AQ |
| 20/12/22 | Nuformix hoping to "initiate discussions with major pharma" in 2023 | AQ |
| 20/12/22 | Nuformix hoping to 'initiate discussions with major pharma' in 2023 | EQ |
| 18/02/20 | Nuformix : Appointment of Dr Karl Keegan | PU |
| Current month | +50.00% | ||
| 3 months | +200.00% | ||
| 6 months | +50.00% | ||
| Current year | -25.00% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0 |
| 3 years | 0 | | 0 |
| 5 years | 0 | | 0.02 |
| Manager | Title | Age | Since |
|---|---|---|---|
Shaun Zulafqar
SEC | Corporate Secretary | - | 28/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Gooding
BRD | Director/Board Member | 53 | 30/06/2022 |
| Director/Board Member | 61 | 01/12/2020 | |
Timothy Metcalfe
CHM | Chairman | 54 | 31/08/2026 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -33.33% | 0.00% | +50.00% | -25.00% | 4.45M | |
| -0.38% | +1.69% | +64.07% | +112.28% | 1,053B | |
| -0.09% | -0.04% | +51.85% | +68.40% | 652B | |
| -0.31% | +0.10% | +20.90% | +70.85% | 468B | |
| -0.85% | +0.98% | +41.29% | +44.38% | 351B | |
| +0.71% | +4.08% | +22.24% | +29.51% | 273B | |
| +1.23% | +0.42% | +14.57% | +12.13% | 254B | |
| +1.40% | +6.77% | +51.84% | +54.30% | 220B | |
| -0.02% | -0.59% | +34.45% | +99.43% | 186B | |
| 0.00% | -10.14% | -29.94% | -60.30% | 170B | |
| Average | +0.14% | +0.30% | +32.13% | +40.60% | 403.04B | |
| Weighted average by Cap. | -0.05% | +1.00% | +40.81% | +66.97% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -3.64M -4.82M -4.23M -4M -6.82M -462M -6.87M -47.82M -18.52M -236M -18.1M -17.71M -759M | -653K -864K -758K -716K -1.22M -82.81M -1.23M -8.57M -3.32M -42.31M -3.24M -3.17M -136M |
| Net Debt | -20.21K -26.76K -23.48K -22.18K -37.83K -2.56M -38.1K -265K -103K -1.31M -100K -98.3K -4.21M | -97.55K -129K -113K -107K -183K -12.38M -184K -1.28M -496K -6.32M -485K -474K -20.33M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change |
|---|---|---|
| 25/09/26 | €0.001000 | -33.33% |
| 24/09/26 | €0.001500 | 0.00% |
| 23/09/26 | €0.001500 | +50.00% |
| 22/09/26 | €0.001000 | 0.00% |
| 21/09/26 | €0.001000 | -33.33% |
- Stock Market
- Stocks
- LVRT Stock
- 1RT Stock
Select your edition
All financial news and data tailored to specific country editions
